Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis

Blood

Volumn 106, Issue 1, 2005, Pages 372-375

  Baldwin, Clinton ^a   Nolan, Vikki G ^b   Wyszynski, Diego F ^b   Ma, Qian Li ^b   Sebastiani, Paola ^b   Embury, Stephen H ^b   Bisbee, Alice ^b   Farrell, John ^b   Farrer, Lindsay ^b   Steinberg, Martin H ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; GENE PRODUCT; LIPOCORTIN 2; PROTEIN KLOTHO; UNCLASSIFIED DRUG;

ARTICLE; BONE METABOLISM; BONE NECROSIS; BONE STRUCTURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 22044456541     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0548     Document Type: Article

References (24)

1. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
2. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop. 1993;289:136-143.
3. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4: 197-201.
4. Gaston M, Smith J, Gallagher D, et al. Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD): Controlled Clinical Trials. 1987;8: 131S-140S.
5. National Center for Biotechnology Information. http://www.ncbi.nlm.nih. gov/.
6. Celera SNP Reference Database. http://www. appliedbiosystems.com.
7. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B-Methodological. 1995;57:289-300.
8. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
9. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68: 978-989.
10. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73: 1162-1169.
11. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003;17: 2393-2403.
12. Yahata K, Mori K, Mukoyama M, et al. Regulation of stanniocalcin 1 and 2 expression in the kidney by klotho gene. Biochem Biophys Res Commun. 2003;310:128-134.
13. Nagai R, Saito Y, Ohyama Y, et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000;57:738-746.
14. Rosendahl A, Pardali E, Speletas M, Ten Dijke P, Heldin CH, Sideras P. Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation. Am J Respir Cell Mol Biol. 2002;27:160-169.
15. Jane JA Jr, Dunford BA, Kron A, et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther. 2002;6:464-470.
16. Sammons J,Ahmed N, El-Sheemy M, Hassan HT. The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev. 2004;13:273-280.
17. Gillette JM, Nielsen-Preiss SM. The role of annexin 2 in osteoblastic mineralization. J Cell Sci. 2004;117:441-449.
18. Jin K, Mao XO, Eshoo MW, et al. cDNA microarray analysis of changes in gene expression induced by neuronal hypoxia in vitro. Neurochem Res. 2002;27:1105-1112.
19. Nolan V, Baldwin C, Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2004;128:266-272.
20. Sebastiani P, Ramoni M, Nolan V, Baldwin C, Steinberg M. Genetic dissection and prognostic modeling of a complex trait: overt stroke in sickle cell anemia. Nat Genet. 2005;37:435-440.
21. Lieberman JR, Berry DJ, Mont MA, et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect. 2003;52:337-355.
22. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65-74.
23. taping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-beta1 -induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002;62:58-64.
24. Callahan JF, Burgess JL, Fornwald JA, et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1)type 1 receptor (ALK5). J Med Chem. 2002;45:999-1001.